Scientific Article
previous document  unige:83973  next document
add to browser collection
Title

Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?

Authors
McLornan, Donal P
Radia, Deepti H
Harrison, Claire N
Published in Future oncology. 2016, vol. 12, no. 6, p. 739-49
Abstract Current treatments for polycythemia vera have remained unchanged for decades with phlebotomy, hydroxycarbamide (also named hydroxyurea) and to a lesser extent interferon being the cornerstones in our therapeutic armamentarium. However, some patients do not respond to, or indeed experience significant side effects to, these current agents and development of alternative therapeutic options is required. Ruxolitinib, a potent JAK1/2 inhibitor, initially approved for myelofibrosis, was recently approved for patients with polycythemia vera refractory or intolerant to hydroxycarbamide. In this article, we review the currently available efficacy and safety data.
Keywords Myeloproliferative neoplasmsOutcomesPolycythemia veraRuxolitinibTreatment
Identifiers
PMID: 26846873
Full text
Article (Published version) (1.7 MB) - document accessible for UNIGE members only Limited access to UNIGE
Citation
(ISO format)
BEAUVERD, Yan et al. Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?. In: Future oncology, 2016, vol. 12, n° 6, p. 739-49. https://archive-ouverte.unige.ch/unige:83973

84 hits

3 downloads

Update

Deposited on : 2016-05-30

Export document
Format :
Citation style :